Latest

Collapsing entry prices and a thickening field of competitors have recast process intensification for biosimilars as a question of commercial survival through speed and agility.

Cytiva’s Pierre-Alain Ruffieux discusses standardization, regionalization, talent gaps, and regulatory pathways shaping advanced biomanufacturing’s future ahead of BIO 2026.

Early clinical data highlight advances in bispecific antibodies and immune modulation, with new findings in Type 2 inflammatory diseases, alopecia areata, and platinum-resistant ovarian cancer.

Bambusa Therapeutics reported positive preliminary phase 1 multiple ascending dose data for BBT002, a bispecific antibody targeting IL-4Rα and IL-5. The investigational therapy demonstrated sustained biomarker suppression, a favorable safety profile, and a half-life supporting extended dosing intervals.

The company reported that all three participants in the 3 µg/kg dose cohort achieved a ≥25% SALT score reduction following single-dose subcutaneous administration, with dose escalation ongoing toward a recommended phase 2 dose.

Interim phase 1 data show CTIM-76 achieved a 29% confirmed overall response rate in heavily pretreated patients with platinum-resistant ovarian cancer, while demonstrating a favorable safety profile and low rates of cytokine release syndrome.

Johnson & Johnson reported that the MonumenTAL-3 trial showed 24-month progression-free survival up to 81.3% and overall survival up to 89.2% with the GPRC5D bispecific combination versus standard of care.

New clinical data highlight advances in endocrine, metabolic, and rare disease drug development, with positive updates from MBX Biosciences, Gan & Lee Pharmaceuticals, and Novartis.

Novartis announced that delpacibart braxlosiran met primary and key secondary biomarker endpoints in the Phase 1/2 FORTITUDE study for facioscapulohumeral muscular dystrophy. The investigational antibody oligonucleotide conjugate is being evaluated as a potential disease-modifying therapy for a condition that currently has no approved treatments.

Gan & Lee has reported positive topline trial results for insulin ludefen in type 2 diabetes and the GLP-1 bofanglutide in obesity.

New developments in CAR-T cell therapy, antibody-drug conjugates, and biosimilars highlight continued innovation across oncology and immunology.

Andrea Zobel and Marco Hogenboom of Cencora World Courier discuss how advances in radiopharmaceutical manufacturing, cancer biology, and specialty logistics are enabling the expansion of targeted radiopharmaceutical therapies into larger patient populations and broader oncology indications.

Phase 3 cancer vaccines and rare disease programs are positioning mRNA therapeutics beyond COVID-19, expanding precision treatment opportunities across oncology and genetic disorders.